Fatty Acid Binding Protein 2 (FABP2) Ancillary Proposal

CompletedOBSERVATIONAL
Enrollment

874

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Type 2 Diabetes Mellitus
Trial Locations (16)

15240

VA Pittsburgh Health Care System, Pittsburgh

24153

VA Medical Center, Salem VA, Salem

33125

VA Medical Center, Miami, Miami

40502

VA Medical Center, Lexington, Lexington

55417

VA Medical Center, Minneapolis, Minneapolis

78229

VA South Texas Health Care System, San Antonio, San Antonio

85012

Carl T. Hayden VA Medical Center, Phoenix

85723

Southern Arizona VA Health Care System, Tucson, Tucson

92161

VA San Diego Healthcare System, San Diego, San Diego

93703

VA Central California Health Care System, Fresno, Fresno

60141-5000

Edward Hines, Jr. VA Hospital, Hines

46202-2884

Richard Roudebush VA Medical Center, Indianapolis, Indianapolis

68105-1873

VA Medical Center, Omaha, Omaha

07018

VA New Jersey Health Care System, East Orange, East Orange

37212-2637

VA Medical Center, Nashville

00921

VA Medical Center, San Juan, San Juan

All Listed Sponsors
collaborator

American Diabetes Association

OTHER

lead

US Department of Veterans Affairs

FED

NCT00256633 - Fatty Acid Binding Protein 2 (FABP2) Ancillary Proposal | Biotech Hunter | Biotech Hunter